CLAUDIA PINTO MARQUES SOUZA DE OLIVEIRA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Gastroenterologia, Faculdade de Medicina - Docente
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
bookPart Obesidade e Comorbidades(2016) SALA, Priscila; BRANISSO, Paula Pessin Fábrega; OLIVEIRA, Claudia Pinto Marques Souza de; WAITZBERG, Dan Linetzky- HCC in patients with NAFLD/NASH(2020) STEFANO, J. T.; MALTA, F. De Mello; CAMPOS, P. B. De; ANDRADE, P. F.; PARANAGUá-VEZZOZO, D. C.; CARRILHO, F. J.; OLIVEIRA, C. P.Hepatocellular carcinoma (HCC) associated with NAFLD has been steadily increasing and non-alcoholic steatohepatitis (NASH) is the most rapidly growing risk for liver transplantation in patients with HCC in the last years. In the vast majority of cases, HCC develops in the context of hepatic cirrhosis, but recent data suggest that there is a proportion of patients with NAFLD who are at high risk for HCC in the absence of cirrhosis. Although no study clearly explains the evolution of NAFLD to HCC, researchers suggest that the most likely mechanism involves fatty acid (FA) accumulation in hepatocytes due to predisposing factors, such as MtS, increased oxidative stress, endoplasmic reticulum (ER) stress, mitochondrial dysfunction and chronic endotoxaemia. Genetic and epigenetic changes in pathogenesis and hepatic carcinogenesis potentially serve as potential diagnostic biomarkers and/or therapeutic targets. MicroRNAs (miRNAs) play a key role in the pathogenesis of HCC related to NAFLD by closely regulating lipid metabolism, glucose homeostasis, cell proliferation, apoptosis, and cell migration and differentiation. In other words, there are currently no guidelines for the screening and early detection of NAFLD-related HCC in the absence of cirrhosis. However, there is an increasing number of HCC cases without cirrhosis. Thus, there is a strong interest in identifying biomarkers to detect early detection of HCC risk related to NAFLD progression. © Springer Nature Switzerland AG 2020.
bookPart Manifestações hepáticas na doença inflamatória intestinal(2015) OLIVEIRA, Cláudia Pinto Marques Souza de; BITTENCOURT, Paulo LisboabookPart Esteato-hepatite não alcoólica(2017) STEFANO, José Tadeu; OLIVEIRA, Claudia Pinto Marques Souza debookPart Doença Hepática Gordurosa não Alcoólica e Doença Hepática Alcoólica(2016) OLIVEIRA, Claudia Pinto Marques Souza de; STEFANO, José Tadeu; MELLO, Evandro Sobroza de; ALVES, Venâncio Avancini FerreirabookPart Doença hepática gordurosa não alcoólica(2014) OLIVEIRA, Lucivalda P. Magalhães de; JESUS, Rosangela Passos de; FREIRE, Thiago Onofre; SANTOS, Raquel Rocha dos; OLIVEIRA, Claudia Pinto Marques Souza debookPart Manifestações hepáticas na doença inflamatória intestinal(2015) OLIVEIRA, Cláudia Pinto Marques Souza de; BITTENCOURT, Paulo Lisboa